Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide/dexamethasone (EPd) vs Pd for treatment of relapsed/refractory multiple myeloma (RRMM): results from the phase 2, randomized open-label ELOQUENT-3 study, EHA 2018, abstract LB2606.
Uitkomsten van COVID-19 na hematopoëtische stamceltransplantatie
apr 2021 | Leukemie, Lymfoom, MM, MPN, Stamceltransplantatie, Virale infecties